^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZX-4081

    i
    Other names: ZX-4081
    Associations

    News

    Trials
    Company:
    Zenshine Pharma
    Drug class:
    PI3Kγ inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A phase 1 study of selective PI3Kγ inhibitor ZX-4081 in patients with advanced solid tumors (AACR 2022)
    Its absorption, distribution, metabolism, and excretion (ADME) and safety profile, through a series of in vitro and in vivo studies, support the clinical development of ZX-4081. Inclusion of combination therapy is planned after obtaining the initial clinical assessment of ZX-4081 on its safety, tolerability, pharmacokinetics, and pharmacodynamics.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • MRC1 (Mannose Receptor C-Type 1)
    |
    ZX-4081